Abelson murine leukemia virus (A-MuLV) is an oncogenic murine retrovirus originally isolated from a prednisolonetreated BALB/c mouse (1) . The A-MuLV genome has since been shown to consist of a 5.6-kilobase RNA which is replication defective and contains sequences homologous to a normal cellular gene c-abl (12, 31) . This genome may be rescued from nonproducer cells by using a replicationcompetent helper virus such as Moloney murine leukemia virus (M-MuLV). The helper virus by itself induces lymphomas of T-cell derivation in a wide variety of mouse strains 3 to 6 months after injection. In contrast, a mixture of M-MuLV and A-MuLV transforms cells primarily of the B-lymphoid lineage within a much shorter period of time, about 3 to 6 weeks after injection.
The tissue specificity and genetics of A-MuLV-induced disease are complex. Most cells transformed by the virus and cultured in vitro have been well characterized as pre-B lymphocytes. They are usually devoid of surface immunoglobulin molecules but contain rearranged immunoglobulin mu genes and cytoplasmic mu heavy chain (reviewed in reference 26). Other potential targets for infection and transformation include mature plasmacytes, previously immortalized fibroblasts, and macrophage-related cells (22, 23, 27) . A-MuLV has also been shown to induce limited proliferation, but not immortalization, of erythroid progenitors in vitro (26, 30) .
In contrast to the relatively wide host range for transformation by the parent (M-MuLV) virus, rapid A-MuLVinduced disease of adult mice was until recently felt to be limited to BALB/c and closely related congenic strains.
Notably, C57BL and C57/Leaden mice were described as resistant. Susceptibility to lymphomagenesis appears to be determined by several factors. One is inheritable in a Mendelian fashion: loci Av-1 and Av-2 were defined by Risser et al. (24) by using a series of BALB/c x C57BL/6 inbred strains. A second important variable is age: most mouse strains develop disease if infected in the first 48 to 72 h of life (1) . A third factor determining the course of tumorigenesis is the route of administration of the virus. Cook (4) observed that, while as previously reported, adult C57BL/Ka mice injected intravenously with A-MuLV remain disease free, animals injected intrathymically develop thymomas bearing the Thy-1 antigen characteristic of T cells. An interesting but difficult-to-interpret aspect of her original report is the finding that, of five cell lines established from thymic tumors, two expressed relatively low levels of Thy-1.2 after culture. The remaining three lines had none. More recently, she has reported (5) establishing several in vitro cell lines expressing various levels of Thy-1.2. Risser et al. (25) have also analyzed a number of cell lines derived from A-MuLVinduced thymomas of several mouse strains. Of their four C57BL/6 lines, two were determined by surface phenotype studies to be of B-lymphoid derivation. The other two were negative for Thy, Ly-1, Ly-2, and B220.
These observations lead to a number of fundamental questions concerning A-MuLV T-lymphomagenesis. ( Flow cytometry and fluorescence microscopy. Immunofluorescent staining of normal thymocytes and tumor cells was carried out as described previously (28) with monoclonal antibodies (MAbs) concentrated by ammonium sulfate precipitation from hybridoma culture supernatants. Clones 53-6.7 (anti-Lyt-2) and 53-7.3 (anti-Lyt-1) were kindly provided by L. Herzenberg, Department of Genetics, Stanford University. Culture supernatant from cells producing MAb GK 1.5, which recognizes antigen L3T4 and blocks several murine helper T-cell functions (9) , was supplied by J. Frelinger, Department of Medicine, Stanford University. Culture supernatant from cells producing MAb MEL-14 was provided by W. M. Gallatin, Department of Pathology, Stanford University. The antigen recognized by MEL-14 is presumed to mediate homing of thymic lymphocytes to peripheral nodes (11) . An antibody, 6B2, detecting the pre-B and B-cell marker B220, and isotype-matched negative controls (anti-nitrophenol antibodies [3] ), were obtained from R. Coffman, DNAX, Palo Alto, Calif. Antibody 6C3, which recognizes a nonviral determinant present on A-MuLVtransformed pre-B cells but not on other tumor cells, was provided by E. Pillemer, Department of Pathology, Stanford University (21) . These first-stage antibodies were used at saturating concentrations and were detected by using a fluorescein isothiocyanate-conjugated goat anti-rat immunoglobulin serum (National Cancer Institute). An anti-H-2Kb
Mab (clone 20-8-4S) directed against a framework determinant (19) (20, 23) .
Southern blotting analysis. DNA was isolated from suspensions of thymocytes prepared as described above by standard methods. Nucleic acid hybridization probes used are shown in Fig. 1 . The A-MuLV defective genome and endogenous c-abl locus were detected by using a plasmid, pAb3Sub3 (12) , derived from the v-abl gene and kindly provided by S. Goff, Columbia University, New York, N. Y. Immunoglobulin,u region rearrangements were detected by hybridization with the insert of a plasmid, pp.27.5, that contains an EcoRI fragment spanning the heavy-chain J region (7) . Plasmid pCK-1, which contains a 5.6-kb EcoRI insert including the mouse kappa J and constant regions, was used to assay immunoglobulin light-chain gene arrangement and was obtained from H. Gershenfeld, Department of Pathology, Stanford University (18) . The T-cell antigen receptor beta chain probe 86T5, including D, J, and C region information, has been previously described (15) . 2 x SSC-0.2% sodium dodecyl sulfate (lx SSC is 150 mM NaCl plus 15 mM sodium citrate) and 0.2x SSC-0.2% sodium dodecyl sulfate at 50 C for 30 to 60 min to elute nonspecifically bound probe and then exposed to XAR-5 film (Eastman Kodak Co., Rochester, N.Y.) for 1 to 5 days at -700C.
RESULTS
Cell surface markers. Mice of two strains previously described as resistant to A-MuLV disease (C57BL/Ka and C57/Leaden [24] ) were injected with the same virus stock. All of the 10 C57BL/Ka animals receiving virus intrathymically developed thymic masses within 30 days. In contrast, none of the 10 C57BL/Ka mice injected intraperitoneally or the 10 C57/Leaden mice injected intrathymically showed any evidence of disease when sacrificed 60 to 70 days later.
As previously reported (4), the majority of cells from primary C57BL/Ka tumors induced by the intrathymic injection of A-MuLV bore the Thy-1.2 antigen. Table 1 and Table  2 summarize the flow cytometry results for several primary tumors and in vitro cell lines established from C57BL/Ka thymomas. Figure 2 shows a typical series of curves for forward light scatter and several differentiation markers for both a primary thymoma (Abl-6) and a cell line derived from a similar tumor (Abl-9L).
Two major conclusions can be drawn from the data summarized in the tables and in the individual histograms for each primary tumor. (i) The Thy-1.2+ cells constituting the bulk of the tumor populations exhibited a rather consistent phenotype. They were large, as evidenced by their forward light scatter characteristics, and stained strongly for Thy-1.2 and Lyt-2 while exhibiting lower but discernible levels of Lyt-1 and L3T4. They thus corresponded well to a subpopulation of normal thymocytes described by Ceredig et al. (2) . These cells, on the basis of sorting and functional analysis, constituted about 20% of normal thymocytes and were classified as immature. Monoclonal antibody MEL-14 (16), postulated to recognize a molecule central to the homing of mature T-lymphoid cells to peripheral nodes, stained 5 to 10% of normal thymocytes. It weakly stained 30 to 50% of the cells of most T-lymphomas in this series (data not shown). The low-intensity staining seen with this antibody is consistent with the thought that these thymomas are at a stage of differentiation earlier than that of T cells about to depart the thymus.
(ii) The second important finding arising from these marker studies is that A-MuLV thymic lymphomas may consist of several populations of cells. Staining of tumor Abl-6 (Fig. 2) revealed the presence of a small number of cells brightly stained by antibody 6B2, which binds pre-B and mature B-lymphoid cells but not T cells (17 These results demonstrate that primary A-MuLV thymoma cells were tumorigenic and that they maintained their T-cell phenotype upon passage in vivo.
Hybridization studies. Previous analyses of A-MuLVinduced lymphomas with hybridization probes derived from v-abl and heavy-chain and light-chain (kappa or lambda) immunoglobulin genes have provided information concerning both the clonality and differentiation state of the neoplasms. Results of such studies in this series of A-MuLV T-lymphomas confirm and extend the cell surface phenotype data.
Hybridizations of primary tumor DNAs with a v-abl- (Fig. 3A) , the A-MuLV transforming genome is present at essentially single-copy levels in the DNAs isolated from A-MuLV thymomas. The c-abl band at 7.0 kilobases provides a convenient copy number control, since the viral and cellular genes are quite closely related by nucleotide sequence and by the lengths of the homologous regions detected by the probe (3). Analysis with HiidIII or E(oRI, however, showed the presence, in at least 6 of the 10 tumors, of several bands with sizes different from c-abl ( Fig. 3B and C) . These bands were present at less than single-copy intensity, suggesting the presence of several subpopulations descended from different cells. In this sense, A-MuLV thymomas were similar to previously described A-MuLV pre-B transformants. Analysis with three immunoglobulin probes, however, clearly distinguished A-MuLV thymomas from typical AMuLV pre-B lymphomas. Hybridization of E(uoRI digests of these DNAs with a p. J-region probe (Fig. 4) . . . _ . to a limited number of additional discrete bands not present in germline DNA (data not shown).
Cell lines. The cell surface phenotypes of four cell lines derived from three A-MuLV-induced thymomas plus a control pre-B cell line, 70Z/3.12, were also analyzed. Flow cytometry curves (Tables 1 and 2 ; Fig. 2 to three copies per cell. An EcoRI digest of both the primary tumor DNA and DNA from the line established from tumor Abl-9 is shown in Fig. 3C . v-abl was found on fragments of different sizes, suggesting that the in vitro cells were not present in large numbers in the original tumor. It should also be noted that lines TAB 1.1 and TAB 1.2, derived from separate cultures of a single primary tumor, contained identical v-abl integration sites as assayed by EcoRI and HindIll digestion.
Results of analysis with the heavy-chain immunoglobulin probes described above clearly demonstrate the presence of p. rearrangements in the lines (Fig. 4) . These data also confirm the impression that TAB 1.1 and TAB 1.2 are derived from the same clone of cells. Similar to the primary tumors and most previously described A-MuLV pre-B lymphomas, the lines showed no evidence of rearrangement for the kappa light chain (data not shown). Finally, the T-cell antigen receptor beta-chain configuration was consistent with the idea that these cells are B-lymphoid in nature ( a single primary tumor were identical with respect to AMuLV integration sites and rearranged immunoglobulin ,i configuration at both alleles. The growth of two indistinguishable lines from separate flasks suggests that the malignant clone existed in vivo and that separate in vitro transformation events did not occur. A more compelling demonstration of that hypothesis might rest upon simultaneous two-color staining of the primary tumors with 6B2 and 6C3 plus the isolation of a much larger number of cell lines. These observations at least suggest a possible explanation for the original findings of Cook.
The tumors described here also differ in a number of respects from other A-MuLV-associated T-lymphoma cells described recently. In a recent paper, Cook (5) has described six cell lines derived from C57BL/Ka mice which express both v-abl RNA and reduced amounts of Thy-1.2 relative to normal thymocytes. None showed detectable levels of Ly-2. In contrast, all 10 tumors we examined expressed high levels of the latter antigen. A possible explanation for this difference is that the cells she analyzed were examined after a minimum of four subcutaneous passages in vivo, followed by several generations in culture. Similar reasoning might also explain the recent experience of Risser et al. (25) .
The selections applied to populations of tumor cells under these conditions are not easily defined and it is possible that the original thymomas were similar to the cells we describe.
Green et al. (13) have examined Thy' v-abl-negative variants of classical A-MuLV pre-B lymphomas. As these cells no longer contain the genome which initiated transformation, they represent examples of selection or neoplastic differentiation still farther removed from the original tumors we have studied.
At the DNA level, the primary cells exhibited mostly unrearranged mu and kappa immunoglobulin genes. Six of the 10 tumors showed no evidence of mu region rearrangements. Of the four which did show evidence, three contain significant numbers (10, 36 , and 59%) of B220+ cells. The rearrangements are again consistent with the idea that AMuLV pre-B transformants are present within these tumors. The last case, Abl-10, is less easily understood. While the phenotyping data suggest that this thymoma is composed predominantly of T cells, at least a subpopulation of cells clearly exhibited a ,u configuration different from germline DNA. Mu rearrangements in T-lymphoma lines (6) and primary tumors (16) have previously been reported; however, the frequency with which this phenomenon occurs in other primary lymphomas is significantly greater than that observed here. In contrast, all of the tumors analyzed here rearranged their T-cell antigen receptor beta-chain genes. These data, in combination with the surface phenotyping results, further establish the differentiation state at which beta-chain genes are rearranged. Further examination of these tumors for RNA expression of alpha-, beta-, and gamma-chain T-cell receptors may prove helpful in defining the control of these genes.
A second important aspect of A-MuLV T-lymphoma biology, the oligoclonal and malignant nature of these tumors, is established by the Southern blotting data and reinjection experiments. The nearly single-copy levels of v-abl detected in thymoma DNA after KpnI digestion suggest that the transforming genome is present in the majority of the primary cells, while use of an enzyme (HindIII or EcoRI) which discriminates integration sites shows that the tumors are descended from a limited number of transformants. This confirmation that v-abl is present in most of these tumor cells is important in the light of results from Grunwald ation of antibodies to possible new tumor-specific antigens, and the construction of cDNA libraries from which differentiation-specific molecules might be identified. 
